Biotech News
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
<p>New York, NY –December 1, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.</p>
<p>The event will feature presentations by the management team and will be followed by a Q&A.</p>
<p>Cellectis Live Webcast</p>
<p>Tuesday, December 13, 2022</p>
<p>7:30am ET/1:30pm CET</p>
<p>To register and access the live webcast: <a href="https://lifescievents.com/event/cellectis-webcast/">https://lifescievents.com/event/cellectis-webcast/</a></p>
<p>Following the live webcast, a replay will be available under the “Events and Webcasts” section on the Investor page of the Company’s website: <a href="https://cellectis.com/en/investors/events-and-webcasts/">https://cellectis.com/en/investors/events-and-webcasts/</a></p>